MINUTES OF THE GENERAL MEETING AT THE 2014 SETAC NORTH AMERICA CONFERENCE (VANCOUVER) HELD ON WEDNESDAY 12TH NOVEMBER 2014, 16:30 – 17:30

PRESENT: 41

APOLOGIES: Mike Williams! Not really worth doing this except for PAG committee members

1 SUMMARY OF EXPERTS WORKSHOP ON ERA OF IONGENIC COMPOUNDS

Mark Bonnell provided a brief summary on what occurred at the expert’s workshop on ionogeneic compounds – a workshop that immediately preceded the SETAC-NA conference. This workshop was born out of a shared interest from the SETAC pharmaceutical advisory group and the SETAC bioaccumulation advisory. The group specifically focused on ADME, fate/effects and ecotoxicity of ionogenic compounds. Four publications will result from this meeting.

Outcome e.g. Members in attendance accept the report through show of hands or one member accepts and seconded by another

RESOLVED/NOTED

2 SPECIAL ISSUE ON PHARMACEUTICALS IN ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY

If you are interested in submitting a manuscript, review article, or synthesis piece for this special issue please contact Mike (mike.williams@csiro.au) by the 14th November with a tentative title, proposed authors and abstract describing your contribution. The final date for submission of manuscripts will be 28th February 2015.

Additionally: the American Association of Pharmaceutical Scientists (AAPS) Journal is seeking articles for a "rolling online" theme issue, Pharmaceuticals and Personal Care Products (PPCPs) in the Environment. The journal’s audience is primarily pharm. scientists and those interested in green chemistry/pharma.

NOTED

3 FUTURE CONFERENCES, WORKSHOPS AND MEETINGS

SESSS
Barcelona
Other meetings to PAG needs to promote/address

Three SETAC Barcelona sessions are especially relevant for the PAG.

NOTED

1) Special symposia on antimicrobials
2) Behavioral session – broad session but will include pharmaceuticals
3) General pharmaceutical sessions; especially looking for direct evidence of real consequences of real environmental exposures

4 OTHER BUSINESS

- Lively discussion on avenues for further research
NOTED

- Several people mentioned a need to better understand pharmaceutical exposure and if pharmaceuticals represented a global concern, or a regional/region-specific concern (based on usage patterns, quality of WWTP, dilution, presence/absence of manufacturing facilities).
- Need for in-stream evidence that shows population level effects for PPCPs. (Analogous to the ELA work by Kidd et al).
- Is there a need for a PBT “reality check”? Do we really understand if these compounds are or are not PBT? (or pseudo PBT)?
## ACTION LIST - TO DO

<table>
<thead>
<tr>
<th>Document Number</th>
<th>Action Number</th>
<th>Follow Up Action Required</th>
<th>Implement. Date</th>
<th>Officer(s) Responsible</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>